Description:
Breast cancer has become the most frequently diagnosed cancer in women, and is the second leading cause of death in women. Although relatively ineffective, Mouse Double Mouse Minute 2 (MDM2) inhibitors blocking the MDM2-p53-binding interphase are currently used for the treatment of advanced breast cancer. This new technology targets a novel direct inhibitor of the MdM2 gene --SP141-- that has shown to possess in vitro and in vivo anti-breast cancer activity, with no seen toxicity.
Reference Number: D-1129
Market Applications:
- Cancer Diagnostics
- In Vitro Diagnostics
Features, Benefits & Advantages:
High throughout screening, and computer aided structure-based rational drug design have shown that SP-141 is a novel therapeutic target for the inhibition of the advancement of breast cancer. SP-141 has shown to inhibit tumor growth in vivo, induce MDM2 protein degradation, and inhibit cell migration in vitro and in vivo.
- Novel, less invasive treatment.
- Less side effects than other drugs currently on the market
Intellectual Property:
A provisional patent was filed on 9/26/14 with the with Serial No. 62/055,796
A US National Stage Application, Serial No. 15513882 was filed 3/23/2017
Development Stage:
Initial clinical tests have been completed and analyzed to obtain information regarding the efficacy and safety of the compound, as well as its therapeutic value.
Researchers:
Dr. Ruiwen Zhang, Pharmacology, Texas Tech University Health Sciences Center, Amarillo, TX
Publications:
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Wang et al., Nat Commun. 2014 Oct 1;5:5086
DOI: 10.1038/ncomms6086.
http://www.nature.com/ncomms/2014/141001/ncomms6086/full/ncomms6086.html
Keywords:
Breast Cancer, Cancer Diagnostics, MDM2 Inhibitor, Cancer Therapy